PDUFA Clock Ticks For FDA Decision On First OTC Acne Ingredient NDA
Executive Summary
Under PDUFA timelines for supplemental NDAs, FDA has until sometime in June to make a decision on Galderma Labs' application to switch its acne treatment adapalene, which would make it the first nonprescription product intended to do more than treat the condition at the surface of the skin. An FDA panel unanimously recommended allowing OTC status.
You may also be interested in...
Nestle's Prospects To Lead OTC Acne Market Gel With Differin Approval
Differin Gel, the first NDA approved OTC acne treatment, could make Nestle the runaway leader in the market. The Swiss firm's Nestle Skin Health business owns Differin maker Galderma and has a majority stake in a JV marketing Proactiv.
Nestle's Prospects To Lead OTC Acne Market Gel With Differin Approval
Differin Gel, the first NDA approved OTC acne treatment, could make Nestle the runaway leader in the market. The Swiss firm's Nestle Skin Health business owns Differin maker Galderma and has a majority stake in a JV marketing Proactiv.
Galderma Pioneers NDA Path Into OTC Acne Treatment Market
FDA on July 8 announces approval for Galderma Laboratories to market Differin Gel 0.1% (adapalene) as an OTC, once-daily topical for treatment of acne by consumers 12 years old and up.